Foresite group exits CASI Pharmaceuticals (CASI) ownership in 13G/A

Rhea-AI Filing Summary

CASI Pharmaceuticals’ large shareholder group reports owning no shares. Foresite Capital Fund VI LP, Foresite Capital Management VI LLC and James Tananbaum each report beneficial ownership of 0 ordinary shares of CASI Pharmaceuticals, representing 0 % of the class as of 12/31/2025.

Each reporting person discloses no sole or shared voting or dispositive power over CASI ordinary shares. They also certify that the securities referenced were not acquired or held to change or influence control of CASI Pharmaceuticals.

Insights

Equity ownership and governance analyst

Key institutional holder now reports zero CASI shares and no voting power.

The reporting group of Foresite Capital Fund VI LP, its management entity and James Tananbaum now disclose beneficial ownership of 0 CASI Pharmaceuticals ordinary shares, equal to 0 % of the class as of 12/31/2025. They also report no sole or shared voting or dispositive power.

This represents a complete exit from reportable ownership levels by a previously disclosable holder, which can alter the company’s shareholder mix and reduce one source of potential long-term support. Actual market impact depends on how and when these holdings were reduced, which this disclosure does not detail.

The group certifies that the securities were not acquired or held to change or influence control, aligning with a passive ownership posture. Subsequent company filings may provide additional context on ownership changes if other investors cross key reporting thresholds.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

CASI Pharmaceuticals, Inc.

(Name of Issuer)

Ordinary Shares, par value $0.0001

(Title of Class of Securities)

G1933S101

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G1933S101

1

Names of Reporting Persons

Foresite Capital Fund VI LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. G1933S101

1

Names of Reporting Persons

Foresite Capital Management VI LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. G1933S101

1

Names of Reporting Persons

James Tananbaum

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CASI Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, F4 100025
Item 2.
(a)	Name of person filing: This Schedule is filed by Foresite Capital Fund VI LP, a Delaware limited partnership ("FCF VI"), Foresite Capital Management VI LLC, a Delaware limited liability company ("FCM VI")and James Tananbaum. The foregoing entities and individuals are collectively referred to as the "Reporting Persons."
(b)	Address or principal business office or, if none, residence: c/o Foresite Capital Management 9200 W. Sunset Boulevard, Suite 515 West Hollywood, CA 90069
(c)	Citizenship: See Row 4 of cover page for each Reporting Person.
(d)	Title of class of securities: Ordinary Shares, par value $0.0001
(e)	CUSIP No.: G1933S101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Row 9 of cover page for each Reporting Person.
(b)	Percent of class: See Row 11 of cover page for each Reporting Person.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Under certain circumstances set forth in the limited partnership agreement of FCF VI and the limited liability company agreement of FCM VI, the partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from the sale of, shares of the Issuer directly or indirectly owned by each such entity of which they are a partner or member.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Foresite Capital Fund VI LP

Signature:	/s/ James Tananbaum
Name/Title:	James Tananbaum, Managing Member of the General Partner
Date:	02/13/2026

Foresite Capital Management VI LLC

Signature:	/s/ James Tananbaum
Name/Title:	James Tananbaum, Managing Member
Date:	02/13/2026

James Tananbaum

Signature:	/s/ James Tananbaum
Name/Title:	James Tananbaum
Date:	02/13/2026

Exhibit Information

Exhibit A Agreement of Joint Filing The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Ordinary Shares of the Issuer shall be filed on behalf of each of the undersigned. Note that a copy of the applicable Agreement of Joint Filing is already on file with the appropriate agencies.

FAQ

What does the CASI (CASI) Schedule 13G/A Amendment No. 3 disclose?

The Schedule 13G/A Amendment No. 3 shows Foresite Capital Fund VI LP, its management entity, and James Tananbaum now report beneficial ownership of 0 ordinary shares of CASI Pharmaceuticals, representing 0 % of the class as of December 31, 2025.

Who are the reporting persons in the CASI (CASI) Schedule 13G/A filing?

The reporting persons are Foresite Capital Fund VI LP, Foresite Capital Management VI LLC, both organized in Delaware, and James Tananbaum, a United States citizen. Together they form the reporting group for this Schedule 13G/A relating to CASI Pharmaceuticals’ ordinary shares.

How many CASI Pharmaceuticals shares do the Foresite entities and James Tananbaum now own?

Each reporting person discloses beneficial ownership of 0 ordinary shares of CASI Pharmaceuticals, with 0 % of the class. They also report zero sole or shared voting power and zero sole or shared dispositive power over CASI ordinary shares.

What does ‘ownership of 5 percent or less’ mean in the CASI (CASI) filing?

The filing indicates the reporting group now has ownership of 5 percent or less of CASI’s ordinary shares, specifically 0 %. This reflects that their holdings no longer meet the threshold that previously required significant ownership reporting.

Do the Foresite entities or James Tananbaum seek to influence control of CASI Pharmaceuticals?

The certification states the securities referenced were not acquired and are not held for the purpose of changing or influencing control of CASI Pharmaceuticals, and not in connection with any transaction having that purpose, other than activities tied to a nomination under Rule 14a-11.

Where are CASI Pharmaceuticals and the reporting persons based in this 13G/A?

CASI Pharmaceuticals’ principal executive offices are listed in Beijing, China. The reporting persons’ principal business office is given as 9200 W. Sunset Boulevard, Suite 515, West Hollywood, California 90069, with the Foresite entities organized in Delaware.